Percutaneous Absorption Preparation for Treating Dementia comprising Memantine Enanthate
The present invention relates to a transdermal absorption preparation containing memantine, consisting of a support layer, a drug-containing layer and an exfoliation layer, wherein the drug-containing layer contains memantine enanthate, a solubilizer and an adhesive base. The transdermal absorption...
Gespeichert in:
Hauptverfasser: | , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; kor |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The present invention relates to a transdermal absorption preparation containing memantine, consisting of a support layer, a drug-containing layer and an exfoliation layer, wherein the drug-containing layer contains memantine enanthate, a solubilizer and an adhesive base. The transdermal absorption preparation for treating dementia, according to the present invention, does not exhibit crystal precipitation, has high skin permeability and not only easily controls a clinically available patch area, but also controls release rate, so as to control absorption rate on the skin, thereby being capable of minimizing skin irritation caused by a drug and minimizing drug loss so as to realize economic advantage and prevent drug overdose.
본 발명은 지지층, 약물함유층, 박리층으로 구성된 메만틴 함유 경피흡수제제에 있어서, 약물함유층은 메만틴 에난트산염, 가용화제 및 점착기제를 함유하는 치매 치료용 경피흡수 제제를 제공한다. 본 발명에 따른 치매 치료용 경피흡수 제제는 결정 석출이 없고, 높은 피부투과도를 나타내며, 임상적으로 사용 가능한 패취 면적을 용이하게 조절할 뿐 아니라, 동시에 방출속도를 조절하여 피부의 흡수속도를 제어함으로써 약물에 의해 나타나는 피부 자극을 최소화할 수 있으며, 약물의 손실을 최소화하여 경제적 이점을 구현함과 동시에 약물의 과다투여를 방지할 수 있다. |
---|